The Many Facets of Metzincins and Their Endogenous Inhibitors: Perspectives on Ovarian Cancer Progression
Ruth M Escalona, Emily Chan, George Kannourakis, Jock K Findlay, Nuzhat Ahmed
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | MDPI | Published : 2018
Approximately sixty per cent of ovarian cancer patients die within the first five years of diagnosis due to recurrence associated with chemoresistance. The metzincin family of metalloproteinases is enzymes involved in matrix remodeling in response to normal physiological changes and diseased states. Recently, there has been a mounting awareness of these proteinases and their endogenous inhibitors, the tissue inhibitors of metalloproteinases (TIMPs), as superb modulators of cellular communication and signaling regulating key biological processes in cancer progression. This review investigates the role of metzincins and their inhibitors in ovarian cancer. We propose that understanding the metz..View full abstract
Ruth M. Escalona and Emily Chan are recipients of the Australian Postgraduate Award. This work was also supported by John Turner Cancer Research Funds to Fiona Elsey Cancer Research Institute, Ballarat, Australia. This work was made possible through the Victorian State Government Operational Infrastructure Support to the Hudson Institute of Medical Research.